Published On: Thu, Sep 8th, 2016

Analysts’ Recent Ratings Updates for Karyopharm Therapeutics (KPTI)

A number of research firms have changed their ratings and price targets for Karyopharm Therapeutics (NASDAQ: KPTI):

9/6/2016 – Karyopharm Therapeutics had its “positive” rating reaffirmed by analysts at Robert W. Baird. They now have a $16.00 price target on the stock.
9/6/2016 – Karyopharm Therapeutics was upgraded by analysts at Vetr from a “hold” rating to a “strong-buy” rating. They now have a $11.00 price target on the stock.
8/31/2016 – Karyopharm Therapeutics was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $11.00 price target on the stock.
8/30/2016 – Karyopharm Therapeutics was upgraded by analysts at Jefferies Group from a “hold” rating to a “buy” rating. They now have a $12.00 price target on the stock, up previously from $9.00. They wrote, “We believe evolving efficacy/safety data, coupled with mgmt’s expertise in the disease area and the continuing unmet need, increases the likelihood (our POS increases to 55 percent from 30 percent) Selinexor will ultimately reach the mkt and generate MM sales of >$500 million by 2025,” analyst Brian Abrahams wrote in a note.Near- And Long-Term PositivesMeanwhile, Selinexor is currently in 35 studies exploring multiple tumor types, increasing the potential to optimize indication, dosing and combination. Based on preclinical results, Abrahams believes that data from next-gen XPO1 inhibitor ‘8602 later this year offer another means to exploit the potential of that agent to target the mechanism with fewer side effects with lower side effects. In addition, the PAK4/NAMPT inhibitor ‘9274 could potentially broaden the company’s long-term opportunity.”Though Selinexor’s narrow therapeutic window remains the biggest limitation, recent studies (e.g., STOMP) at more optimized doses appear based on our analysis to suggest more acceptable AEs,”
8/30/2016 – Karyopharm Therapeutics had its price target lowered by analysts at S&P Equity Research from $9.06 to $7.55.
8/18/2016 – Karyopharm Therapeutics is now covered by analysts at HC Wainwright. They set a “buy” rating and a $15.00 price target on the stock.
8/9/2016 – Karyopharm Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “
8/6/2016 – Karyopharm Therapeutics was given a new $20.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
8/4/2016 – Karyopharm Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $14.00 price target on the stock.
7/21/2016 – Karyopharm Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “
7/12/2016 – Karyopharm Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) opened at 9.14 on Thursday. Karyopharm Therapeutics Inc. has a 1-year low of $4.83 and a 1-year high of $19.41. The firm’s market capitalization is $328.94 million. The company has a 50 day moving average of $7.65 and a 200 day moving average of $8.08.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Thursday, August 4th. The company reported ($0.84) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by $0.08. Analysts forecast that Karyopharm Therapeutics Inc. will post ($3.22) EPS for the current year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/08/analysts-recent-ratings-updates-for-karyopharm-therapeutics-kpti.html

In related news, major shareholder Ltd Chione sold 7,074 shares of the firm’s stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $8.51, for a total value of $60,199.74. Following the sale, the insider now owns 8,568,744 shares of the company’s stock, valued at $72,920,011.44. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 14.79% of the stock is currently owned by corporate insiders.
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

Receive News & Ratings for Karyopharm Therapeutics Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Karyopharm Therapeutics Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>